Patients’ Understanding and Attitudes Towards Infliximab and Etanercept Biosimilars: Result of a UK Web-Based Survey

Aladul, Mohammed I.; Fitzpatrick, R; Chapman, Stephen

doi:10.1007/s40259-017-0238-1

Cited by 25 publications

(28 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 2014-2015 European survey of 1059 patients with IBD found that approximately 36% had heard of biosimilars [168], and 49% of Belgian patients with RA (surveyed in 2016) reported familiarity with biosimilars [169]. In a 2017 UK survey of patients with RA and AS, 66% and 80% of respondents receiving RPs or biosimilars, respectively, understood what biosimilars were [170]. Among European patients with IBD who had heard of biosimilars, safety and efficacy were the most common concerns (47% and 39%, respectively), whereas around one-quarter of respondents had no specific concerns [168].…”

Section: Patients' Perspective: Improved Information Sharing May Encomentioning

confidence: 99%

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

Kim

Alten

Avedano³

et al. 2020

Drugs

View full text Add to dashboard Cite

Biologics have transformed the treatment of immune-mediated inflammatory diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars-biologic medicines with no clinically meaningful differences in safety or efficacy from licensed originators-can stimulate market competition and have the potential to expand patient access to biologics within the parameters of treatment recommendations. However, maximizing the benefits of biosimilars requires cooperation between multiple stakeholders. Regulators and developers should collaborate to ensure biosimilars reach patients rapidly without compromising stringent quality, safety, or efficacy standards. Pharmacoeconomic evaluations and payer policies should be updated following biosimilar market entry, minimizing the risk of imposing nonmedical barriers to biologic treatment. In RA, disparities between treatment guidelines and national reimbursement criteria could be addressed to ensure more uniform patient access to biologics and enable rheumatologists to effectively implement treat-to-target strategies. In IBD, the cost-effectiveness of biologic treatment earlier in the disease course is likely to improve when biosimilars are incorporated into pharmacoeconomic analyses. Patient understanding of biosimilars is crucial for treatment success and avoiding nocebo effects. Full understanding of biosimilars by physicians and carefully considered communication strategies can help support patients initiating or switching to biosimilars. Developers must operate efficiently to be sustainable, without undermining product quality, the reliability of the supply chain, or pharmacovigilance. Developers should also facilitate information sharing to meet the needs of other stakeholders. Such collaboration will help to ensure a sustainable future for both the biosimilar market and healthcare systems, supporting the availability of effective treatments for patients.

show abstract

Section: Patients' Perspective: Improved Information Sharing May Encomentioning

confidence: 99%

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

Kim

Alten

Avedano³

et al. 2020

Drugs

View full text Add to dashboard Cite

show abstract

“…They identified that the majority of patients were satisfied with their current therapy; however, patient concerns regarding biosimilars included not enough knowledge about the therapy, potential side effects, and potential long‐term problems (eg, loss of disease activity control) . Aladul and colleagues reported that patients with RA or AS in their United Kingdom survey who were receiving a biosimilar were optimistic about biosimilars’ safety, efficacy, and switching, whereas patients who were receiving the originator biologic were reluctant to switch to a biosimilar . Peyrin‐Biroulet and colleagues reported from their survey of European patients with inflammatory bowel disease who were receiving the bio‐originator that most patients were not familiar with biosimilars and, of those who were, doubts and concerns about the safety and efficacy of biosimilars were raised .…”

Section: Discussionmentioning

confidence: 99%

“…Although switching studies have identified similar safety and efficacy effects between infliximab and infliximab‐dyyb , and though infliximab‐dyyb offers an efficacious and potentially less expensive treatment option, only a limited number of non‐US studies have evaluated patient perspectives and opinions on the infliximab to infliximab‐dyyb switch . In 2017, Kaiser Permanente Colorado (KPCO), an integrated health care delivery system , implemented an infliximab to infliximab‐dyyb switch in patients with RA, PsA, and/or AS.…”

Section: Introductionmentioning

confidence: 99%

Patient Perspectives on Switching from Infliximab to Infliximab‐dyyb in Patients with Rheumatologic Diseases in the United States

Chau

Delate

Ota

et al. 2019

ACR Open Rheumatology

View full text Add to dashboard Cite

Objective The introduction of biosimilars for rheumatologic diseases (RDs) has provided a potentially lower‐cost therapy compared with their bio‐originator products; however, adoption of biosimilars may be challenged by patient perceptions. The objective of this study was to describe patients’ perspectives of switching from infliximab to infliximab‐dyyb. Methods This was a survey of adult patients with RDs who qualified for switching from infliximab to infliximab‐dyyb therapy between September 1 2017 and January 31 2018. Verbal consent was obtained prior to administration of a telephone survey. Survey questions were focused on the safety, efficacy, and knowledge of biosimilar therapy. Results A total of 108 patients were identified with 52 (48%) patients consenting to study participation. Forty (77%) and 12 (23%) patients reported switching and not switching, respectively, to infliximab‐dyyb. Regarding disease control, most respondents (80%) were satisfied to very satisfied with the switch to infliximab‐dyyb. Major concerns reported for switching included not knowing enough about the medication (38%), potential side effects (35%), and loss of disease activity control (35%). Conclusion Overall, patients reported satisfaction with switching from infliximab to infliximab‐dyyb, but concerns regarding safety and efficacy were expressed. Patient involvement in the switching decision‐making process may allay concerns and enhance biosimilar uptake.

show abstract

“…No patients or members of the public were involved in this study, but the questions were influenced by the results of the authors’ previously published patients’ web survey. 21 …”

Section: Methodsmentioning

confidence: 99%

Healthcare professionals’ perceptions and perspectives on biosimilar medicines and the barriers and facilitators to their prescribing in UK: a qualitative study

2018

Self Cite

View full text Add to dashboard Cite

ObjectiveTo investigate UK healthcare professionals’ perceptions and perspectives towards biosimilar infliximab, etanercept and insulin glargine and the potential barriers and facilitators to their prescribing.DesignA cross-sectional qualitative study design was used.SettingFive hospitals within the West Midlands area in UK.Interventions30 min face-to-face, semistructured interviews of healthcare professionals.Participants22 healthcare professionals (consultants, nurses and pharmacists) participated in the semistructured interviews.OutcomesParticipants’ opinion and attitudes about biosimilars and the barriers and facilitators to the prescribing of infliximab, etanercept and insulin glargine biosimilars in gastroenterology, rheumatology and diabetology specialties.ResultsThis study showed that UK healthcare professionals had good knowledge of biosimilars and were content to initiate them. Healthcare professionals disagreed with biosimilar auto-substitution at pharmacy level and multiple switching. Subtle differences among healthcare professionals were identified in the acceptance of switching stable patients, indication extrapolation and cost savings sharing.ConclusionSafety and efficacy concerns, patients’ opinion and how cost savings were shared were the identified barriers to considering prescribing biosimilars. Real-life data and financial incentives were the suggested facilitators to increase biosimilar utilisation.

show abstract

Patients’ Understanding and Attitudes Towards Infliximab and Etanercept Biosimilars: Result of a UK Web-Based Survey

Cited by 25 publications

References 12 publications

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

Patient Perspectives on Switching from Infliximab to Infliximab‐dyyb in Patients with Rheumatologic Diseases in the United States

Healthcare professionals’ perceptions and perspectives on biosimilar medicines and the barriers and facilitators to their prescribing in UK: a qualitative study

Contact Info

Product

Resources

About